Dr. Carey on Everolimus in Metastatic Breast Cancer

Lisa A. Carey, MD
Published Online: Friday, April 5, 2013
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

Everolimus, an mTOR inhibitor, has demonstrated benefit to women with acquired endocrine resistance. These patients are treated with an aromatase inhibitor, respond briefly, but eventually develop resistance. It has been seen, Carey says, that adding everolimus to any aromatase inhibitor still produces beneficial results with regard to progression-free survival. Everolimus, and targeting the mTOR pathway in general, is a promising arena in metastatic acquired resistance to endocrine therapies.

Future studies will move everolimus into the adjuvant setting and analyze whether it helps to augment the effectiveness of endocrine therapy.

Online CME Activities
Free CME from PER
31st Annual Miami Breast Cancer Conference® Clinical Vignette Series
Clinical Vignettes Series: Hematologic Malignancies
Miami Lung Cancer Conference™ Medical Crossfire®
Community Practice Connections: 18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
More Reading
Publications
$auto_registration$